6186 Federal Register / Vol. 73, No. 22 / Friday, February 1, 2008 / Notices 

Submission’’ or ‘‘More Search Options’’

to find the information collection 

document(s) accepting comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number lll, Room C4–26–

05, 7500 Security Boulevard, Baltimore, 

Maryland 21244–1850. 

Dated: January 25, 2008. 

Michelle Shortt, 

Director, Regulations Development Group, 

Office of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. E8–1810 Filed 1–31–08; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

President’s Committee for People With 

Intellectual Disabilities; Notice of 

Quarterly Meeting 

AGENCY: President’s Committee for 

People with Intellectual Disabilities 

(PCPID); Administration for Children 

and Families; Department of Health and 

Human Services. 

ACTION: Notice of Quarterly Meeting. 

DATES: February 15, 2008, from 3:30 

p.m. to 5:30 p.m. EST. The meeting will 

be conducted via conference call and 

will be open to the public using the 

dial-in information provided below. 

ADDRESSES: The conference call may be 

accessed on the date and time indicated 

by dialing 888–677–5720, passcode: 

1397797. 

Agenda: PCPID will meet to finalize 

the 2007 Report to the President and to 

hear a briefing on the final report of the 

Ticket to Work and Work Incentives 

Advisory Panel. 

FOR FURTHER INFORMATION CONTACT: 

Sally D. Atwater, Executive Director, 

President’s Committee for People with 

Intellectual Disabilities, The Aerospace 

Center, Second Floor, West, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447. Telephone: 202–619–0634, 

Fax: 202–205–9591. E-mail: 

satwater@acf.hhs.gov. 

SUPPLEMENTARY INFORMATION: PCPID 

acts in an advisory capacity to the 

President and the Secretary of Health 

and Human Services on a broad range 

of topics relating to programs, services 

and supports for persons with 

intellectual disabilities. PCPID, by 

Executive Order, is responsible for 

evaluating the adequacy of current 

practices in programs, services and 

supports for persons with intellectual 

disabilities, and for reviewing legislative 

proposals that impact the quality of life 

experienced by citizens with 

intellectual disabilities and their 

families. 

Dated: January 25, 2008. 

Sally D. Atwater, 

Executive Director, President’s Committee for 

People with Intellectual Disabilities. 

[FR Doc. E8–1809 Filed 1–31–08; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Request for Notification from Industry 

Organizations Interested in 

Participating in the Selection Process 

for a Nonvoting Industry 

Representative on the Blood Products 

Advisory Committee and Request for 

Nominations for a Nonvoting Industry 

Representative on the Blood Products 

Advisory Committee 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting that 

any industry organizations interested in 

participating in the selection of a 

nonvoting industry representative to 

serve on the Blood Products Advisory 

Committee, Center for Biologics 

Evaluation and Research (CBER), notify 

FDA in writing. A nominee may either 

be self-nominated or nominated by an 

organization to serve as a nonvoting 

industry representative. Nominations 

will be accepted for an upcoming 

vacancy on September 30, 2008, 

effective with this notice. 

DATES: Any industry organization 

interested in participating in the 

selection of an appropriate nonvoting 

member to represent industry interests 

must send a letter stating the interest to 

FDA by March 3, 2008, for vacancies 

listed in the notice. Concurrently, 

nomination material for prospective 

candidates should be sent to FDA by 

March 3, 2008. 

ADDRESSES: All letters of interest and 

nominations should be submitted in 

writing to Donald W. Jehn (see FOR

FURTHER INFORMATION CONTACT). 

FOR FURTHER INFORMATION CONTACT: 

Donald W. Jehn, Division of Scientific 

Advisors and Consultants, Center for 

Biologics Evaluation and Research, 

Food and Drug Administration (HFM–

71), 1401 Rockville Pike, Rockville, MD 

20892, 301–827–1277, 

donald.jehn@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

agency requests nominations for a 

nonvoting industry representative to the 

Blood Products Advisory Committee. 

I. Function 

The Blood Products Advisory 

Committee reviews and evaluates 

available data concerning the safety, 

effectiveness, and appropriate use of 

blood products derived from blood and 

serum or biotechnology which are 

intended for the use in the diagnosis, 

prevention, or treatment of human 

diseases, and, as required, any other 

product for which FDA has regulatory 

responsibility. The committee also 

advises the Commissioner of Food and 

Drugs (the Commissioner) on its 

findings regarding the safety, 

effectiveness, and labeling of the 

products, clinical and laboratory studies 

involving such products, the affirmation 

or revocation of biological product 

licenses, and on the quality and 

relevance of FDA’s research program 

which provides the scientific support 

for regulating these agents. 

II. Selection Procedure 

Any blood products industry, 

association, or organization interested in 

the selection of an appropriate 

nonvoting member to represent industry 

interests should send a letter stating that 

interest to the FDA contact (see FOR

FURTHER INFORMATION CONTACT) within 

30 days of publication of this document 

(see DATES). Within the subsequent 30 

days, FDA will send a letter to each 

organization that has expressed an 

interest, attaching a complete list of all 

such organizations and a list of all 

nominees along with their current 

resumes. The letter will also state that 

it is the responsibility of the interested 

organizations to confer with one another 

and to select a primary and alternate 

candidate, within 60 days after the 

receipt of the FDA letter, and the 

primary candidate will serve as the 

nonvoting member to represent industry 

interests for the Blood Products 

Advisory Committee. The interested 

organizations are not bound by the list 

of nominees in selecting a candidate. 

However, if no individual is selected 

within 60 days, the Commissioner will 

select the nonvoting member to 

represent industry interests. 

III. Application Procedure 

Individuals may self nominate and/or 

an organization may nominate one or 

more individuals to serve as a nonvoting 

mstockstill on PROD1PC66 with NOTICES